9
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Highlights

          • Nearly 75 % of the survey respondents indicated that they were likely to accept COVID-19 vaccine.

          • 48 % of the survey respondents were likely to accept to participate in a vaccine clinical trial if asked against SARS-CoV-2 infections.

          • Healthcare workers were more prone to get vaccinated against COVID-19 than non HCWs.

          Abstract

          Introduction

          The world is facing the COVID-19 pandemic. The development of a vaccine is challenging. We aimed to determine the proportion of people who intend to get vaccinated against COVID-19 in France or to participate in a vaccine clinical trial.

          Methods

          We conducted an anonymous on-line survey from the 26th of March to the 20th of April 2020. Primary endpoints were the intention to get vaccinated against COVID-19 if a vaccine was available or participate in a vaccine clinical trial.

          Results

          Three thousand two hundred and fifty nine individuals answered the survey; women accounted for 67.4 % of the respondents. According to their statements, 2.512 participants (77.6%, 95 % CI 76.2-79 %) will certainly or probably agree to get vaccinated against COVID-19. Older age, male gender, fear about COVID-19, being a healthcare worker and individual perceived risk were associated with COVID-19 vaccine acceptance. Vaccine hesitancy was associated with a decrease in COVID-19 vaccine acceptance. One thousand and five hundred and fifty respondents (47.6 % 95 % CI 45.9-49.3 %) will certainly or probably agree to participate in a COVID-19 vaccine clinical trial. Older age, male gender, being a healthcare worker and individual perceived risk were associated with potential acceptance to participate in a COVID-19 vaccine clinical trial. Vaccine hesitancy was associated with refusal for participation in a COVID-19 vaccine clinical trial.

          Conclusions

          Nearly 75 % and 48 % of the survey respondents were respectively likely to accept vaccination or participation in a clinical trial against COVID-19. Vaccine hesitancy will be the major barrier to COVID-19 vaccine uptake.

          Related collections

          Author and article information

          Journal
          Vaccine
          Vaccine
          Vaccine
          Elsevier Ltd.
          0264-410X
          1873-2518
          17 September 2020
          17 September 2020
          Affiliations
          [a ]Centre d’investigation clinique-INSERM 1408, University Hospital of Saint-Etienne, France
          [b ]Department of General Practice, Faculté de Médecine Jacques Lisfranc, Université Jean Monnet, Université de Lyon, Saint-Etienne, France
          [c ]Groupe Immunité des Muqueuses et Agents Pathogènes, Université Jean Monnet, Université de Lyon, Saint-Etienne, France
          [d ]PRESAGE Insitute, Université de Lyon, Saint-Etienne, France
          Article
          S0264-410X(20)31201-9
          10.1016/j.vaccine.2020.09.041
          7498238
          32988688
          00987e32-a2c1-4ecd-a3e3-577564af202a
          © 2020 Elsevier Ltd. All rights reserved.

          Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

          History
          : 6 July 2020
          : 7 September 2020
          : 14 September 2020
          Categories
          Article

          Infectious disease & Microbiology
          covid-19,vaccine,vaccine hesitancy,pandemics,sars-cov-2
          Infectious disease & Microbiology
          covid-19, vaccine, vaccine hesitancy, pandemics, sars-cov-2

          Comments

          Comment on this article